Petition to Delay Biosimilar Game in U.S. Picks up Steam
By Mari Serebrov
Friday, February 15, 2013
While other countries are building a strong lineup of biosimilars, the U.S. entry into the game could be delayed until 2022 if Abbott Laboratories succeeds in making its case that allowing a biosimilar of a reference drug approved before March 23, 2010, would be an illegal government taking of private property.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.